HomeInsightsStock Comparison

Abbott India Ltd vs Alivus Life Sciences Ltd Stock Comparison

Abbott India Ltd vs Alivus Life Sciences Ltd Stock Comparison

Last Updated on: May 24, 2025

Key Highlights

  • The Latest Trading Price of Abbott India Ltd is ₹ 30818 as of 23 May 15:30.
  • The P/E Ratio of Abbott India Ltd changed from 55.4 on March 2020 to 47.7 on March 2024 . This represents a CAGR of -2.95% over 5 yearsThe P/E Ratio of Alivus Life Sciences Ltd changed from 13.4 on March 2022 to 20.2 on March 2024 . This represents a CAGR of 14.66% over 3 years.
  • The Market Cap of Abbott India Ltd changed from ₹ 32842 crore on March 2020 to ₹ 57260 crore on March 2024 . This represents a CAGR of 11.76% over 5 yearsThe Market Cap of Alivus Life Sciences Ltd changed from ₹ 5624 crore on March 2022 to ₹ 9499 crore on March 2024 . This represents a CAGR of 19.09% over 3 years.
  • The revenue of Abbott India Ltd for the Mar '25 is ₹ 1680 crore as compare to the Dec '24 revenue of ₹ 1686 crore. This represent the decline of -0.32% The revenue of Alivus Life Sciences Ltd for the Mar '25 is ₹ 659.63 crore as compare to the Dec '24 revenue of ₹ 652.3 crore. This represent the growth of 1.12%.
  • The ebitda of Abbott India Ltd for the Mar '25 is ₹ 504.56 crore as compare to the Dec '24 ebitda of ₹ 507.84 crore. This represent the decline of -0.65% The ebitda of Alivus Life Sciences Ltd for the Mar '25 is ₹ 208.52 crore as compare to the Dec '24 ebitda of ₹ 200.76 crore. This represent the growth of 3.87%.
  • The net profit of Abbott India Ltd changed from ₹ 290.24 crore to ₹ 367.04 crore over 8 quarters. This represents a CAGR of 12.45% The net profit of Alivus Life Sciences Ltd changed from ₹ 135.45 crore to ₹ 141.87 crore over 8 quarters. This represents a CAGR of 2.34% .
  • The Dividend Payout of Abbott India Ltd changed from 89.6 % on March 2020 to 72.53 % on March 2024 . This represents a CAGR of -4.14% over 5 yearsThe Dividend Payout of Alivus Life Sciences Ltd changed from 61.46 % on March 2022 to 58.56 % on March 2024 . This represents a CAGR of -1.60% over 3 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Abbott India Ltd

  • Abbott India Ltd. is one of the leading multinational pharmaceutical companies in India and operates with an owned manufacturing facility in Goa and various independent contract/third party manufacturers based across the country.
  • The Company sells its products through independent distributors primarily within India.
  • It provides products and solutions across various therapeutic areas such as Women's Health, Gastroenterology, Central Nervous System, Metabolics, Multi-Specialty, Vaccines, Consumer Health, etc.
  • Its global products include Brufen, Prothiaden, Thyronorm and Leptos. The company has four divisions.
  • The Primary Care division markets products in the areas of pain management and gastroenterology.

About Alivus Life Sciences Ltd

  • Glenmark Life Sciences Limited was incorporated as Zorg Laboratories Private Limited', on June 23, 2011 at Pune and was granted the Certificate of Incorporation by the Registrar of Companies, Maharashtra at Pune.
  • Subsequently, the Company was acquired by Glenmark Pharmaceuticals Limited through a Share Purchase Agreement dated 04 July 2018 and the name of the Company was changed to Glenmark Life Sciences Private Limited' dated 10 August 2018.
  • A shareholders' resolution was passed on 13 August 2018 to convert the Company from a Private Limited Company to a Public Limited Company and a fresh Certificate of Incorporation dated 28 August 2018 was issued by the RoC. The Company is a wholly owned Subsidiary of Glenmark Pharmaceuticals Limited.
  • The Company acquired API Division of Glenmark Pharmaceuticals Limited (the parent company) on 01 January, 2019.

Abbott India Ltd News Hub

News

Abbott India Ltd up for five straight sessions

Abbott India Ltd rose for a fifth straight session today. The stock is quoting at Rs 31190...

Read more

21 May 2025 13:00

News

Abbott India AGM scheduled

Abbott India announced that the 81th Annual General Meeting(AGM) of the company will be he...

Read more

16 May 2025 09:25

News

Board of Abbott India recommends final dividend

Abbott India announced that the Board of Directors of the Company at its meeting held on 1...

Read more

16 May 2025 09:25

News

Abbott India rises after Q4 PAT jumps 28% YoY to Rs 367 cr; declares dividend of Rs 475 /sh

Profit before tax (PBT) stood at Rs 482.71 crore in Q4 FY25, up 23.9% YoY. Total expenses ...

Read more

16 May 2025 10:58

News

Abbott India to conduct board meeting

Abbott India will hold a meeting of the Board of Directors of the Company on 15 May 2025. ...

Read more

07 May 2025 14:26

News

Abbott India appoints senior management personnel

Abbott India has appointed Anushree Kunhambu - Associate Director - New Product Introducti...

Read more

16 Apr 2025 09:38

Alivus Life Sciences Ltd News Hub

News

Board of Alivus Life Sciences recommends final dividend

Alivus Life Sciences announced that the Board of Directors of the Company at its meeting h...

Read more

16 May 2025 09:27

News

Alivus Life Sciences to hold board meeting

Alivus Life Sciences will hold a meeting of the Board of Directors of the Company on 15 Ma...

Read more

09 May 2025 10:57

News

Alivus Life Sciences allots 92,096 equity shares under ESOS

Alivus Life Sciences has allotted 92,096 equity shares under ESOS on 30 April 2025. Conseq...

Read more

30 Apr 2025 19:38

News

Alivus Life jumps after Q3 PAT climbs 15% YoY to Rs 137 cr

Profit before tax (PBT) climbed 15.22% YoY to Rs 185.14 crore in Q3 FY25. For Q3FY25, EBIT...

Read more

23 Jan 2025 15:01

News

Alivus Life Sciences Ltd leads gainers in 'A' group

Avantel Ltd, Sunteck Realty Ltd, Spandana Sphoorty Financial Ltd and Jai Corp Ltd are amon...

Read more

21 Jan 2025 12:00

News

Glenmark Life Sciences renamed as Alivus Life Sciences

Glenmark Life Sciences announced its change of identity to Alivus Life Sciences, marking a...

Read more

20 Jan 2025 10:18

SWOT Analysis Of Abbott India Ltd

Strength

1

S

Weakness

0

W

Opportunity

0

O

Threats

0

T

SWOT Analysis Of Alivus Life Sciences Ltd

Strength

2

S

Weakness

2

W

Opportunity

1

O

Threats

0

T

BlinkX Score for Abbott India Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Alivus Life Sciences Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Abbott India Ltd and Alivus Life Sciences Ltd

Which company has a larger market capitalization, Abbott India Ltd or Alivus Life Sciences Ltd?

Market cap of Abbott India Ltd is 65,488 Cr while Market cap of Alivus Life Sciences Ltd is 13,674 Cr

What are the key factors driving the stock performance of Abbott India Ltd and Alivus Life Sciences Ltd?

The stock performance of Abbott India Ltd and Alivus Life Sciences Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Abbott India Ltd and Alivus Life Sciences Ltd?

As of May 24, 2025, the Abbott India Ltd stock price is INR ₹30818.0. On the other hand, Alivus Life Sciences Ltd stock price is INR ₹1115.15.

How do dividend payouts of Abbott India Ltd and Alivus Life Sciences Ltd compare?

To compare the dividend payouts of Abbott India Ltd and Alivus Life Sciences Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions